aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing therapies for rare diseases using CRISPR gene editing technology. Headquartered in Cambridge, Massachusetts, with facilities in Boulder, Colorado, Editas aims to transform the treatment landscape for genetic disorders through innovative gene editing solutions.
Editas Medicine has achieved significant milestones in advancing CRISPR-based therapies, positioning itself as a leader in the biotech industry. The company's pioneering work has garnered attention and support from notable investors and scientific communities, driving forward the potential for groundbreaking treatments in genetic medicine.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Therapies, Gene Editing
Technology
Biotech, GenAI
Model Types
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Editas Medicine founded?
Editas Medicine was founded in 2013.
Where is Editas Medicine's headquarters located?
Editas Medicine's headquarters is located in Cambridge, MA, US.
When was Editas Medicine's last funding round?
Editas Medicine's most recent funding round was for $125M (USD) in June 2023.
How many employees does Editas Medicine have?
Editas Medicine has 226 employees as of Feb 6, 2024.
How much has Editas Medicine raised to-date?
As of July 05, 2023, Editas Medicine has raised a total of $931.6M (USD) since Jun 14, 2023.
Add Comparison
Total Raised to Date
$931.6M
USD
Last Update Jun 14, 2023
Last Deal Details
$125M
USD
Jun 14, 2023
Post Ipo Equity
Total Employees Over Time
226
As of Feb 2024
Editas Medicine Address
11 Hurley Street
Cambridge,
Massachusetts
02141-2110
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts